Abstract
A series of piperidyl-thienyl & 2-pyrazoline derivatives of quinolyl-thienyl chalcones were tested to observe the structural characteristics for the monoamine oxidase inhibitory (MAO) activity. In both these series, a diverse range of substituted thiophenes are used which enable the structure activity relationship. The compounds showed enhanced inhibition against MAO-A & B as compared to reference compounds. Compound 1c exhibited most potent MAO-A inhibition having IC50 value of 0.062 M, while 1j showed excellent inhibitory potency against MAO-B having IC50 value of 0.088 M. The present investigation demonstrated that among piperidyl-thienyl chalcones, almost all the compounds exhibit significant MAO-A inhibition, thus may have antidepressant activity. Whereas among the 2-pyrazoline derivatives of chal-cones, many compounds revealed MAOB inhibition and hence may be applied in the control of senile dementia. Molecular docking studies were carried out against human MAO-A and MAO-B to rationalize important binding site interactions.
Keywords: Antidepressant activity, molecular docking, monoamine oxidase, piperidyl-thienyl derivatives, quinolyl-thienyl chalcones.
Medicinal Chemistry
Title:Monoamine Oxidase Inhibition and Molecular Modeling Studies of Piperidyl-thienyl and 2-Pyrazoline Derivatives of Chalcones
Volume: 11 Issue: 5
Author(s): Sumera Zaib, Syed Umar Farooq Rizvi, Sana Aslam, Matloob Ahmad, Mariya al-Rashida and Jamshed Iqbal
Affiliation:
Keywords: Antidepressant activity, molecular docking, monoamine oxidase, piperidyl-thienyl derivatives, quinolyl-thienyl chalcones.
Abstract: A series of piperidyl-thienyl & 2-pyrazoline derivatives of quinolyl-thienyl chalcones were tested to observe the structural characteristics for the monoamine oxidase inhibitory (MAO) activity. In both these series, a diverse range of substituted thiophenes are used which enable the structure activity relationship. The compounds showed enhanced inhibition against MAO-A & B as compared to reference compounds. Compound 1c exhibited most potent MAO-A inhibition having IC50 value of 0.062 M, while 1j showed excellent inhibitory potency against MAO-B having IC50 value of 0.088 M. The present investigation demonstrated that among piperidyl-thienyl chalcones, almost all the compounds exhibit significant MAO-A inhibition, thus may have antidepressant activity. Whereas among the 2-pyrazoline derivatives of chal-cones, many compounds revealed MAOB inhibition and hence may be applied in the control of senile dementia. Molecular docking studies were carried out against human MAO-A and MAO-B to rationalize important binding site interactions.
Export Options
About this article
Cite this article as:
Zaib Sumera, Farooq Rizvi Umar Syed, Aslam Sana, Ahmad Matloob, al-Rashida Mariya and Iqbal Jamshed, Monoamine Oxidase Inhibition and Molecular Modeling Studies of Piperidyl-thienyl and 2-Pyrazoline Derivatives of Chalcones, Medicinal Chemistry 2015; 11 (5) . https://dx.doi.org/10.2174/1573406410666141229101130
DOI https://dx.doi.org/10.2174/1573406410666141229101130 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Health Service Utilization and Costs of Depressive Symptoms in Late Life - A Systematic Review
Current Pharmaceutical Design Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Editorial [Hot Topic: Anti-Amyloidogenic/Protein-Misfolding Therapies in Amyloidosis and Other Protein-Misfolding Disorders (Executive Editor: Masahito Yamada)]
Current Pharmaceutical Design Nutraceuticals, Nutritional Therapy, Phytonutrients, and Phytotherapy for Improvement of Human Health: A Perspective on Plant Biotechnology Application
Recent Patents on Biotechnology A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Current Alzheimer Research Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design Pathophysiology of Platelet Resistance to Anti-Aggregating Agents in Insulin Resistance and Type 2 Diabetes: Implications for Anti-Aggregating Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Adolescent HIV-1 Transgenic Rats: Evidence for Dopaminergic Alterations in Behavior and Neurochemistry Revealed by Methamphetamine Challenge
Current HIV Research Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design AICD Nuclear Signaling and Its Possible Contribution to Alzheimers Disease
Current Alzheimer Research Lipid Biomarkers in Alzheimer's Disease
Current Alzheimer Research Comparative Neurophysiologic Study of Pain in Patients with Parkinson's Disease and Patients with Persistent Pain After Spinal Surgery
Neuroscience and Biomedical Engineering (Discontinued) Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Can Apolipoproteins and Complement Factors be Biomarkers of Alzheimer’s Disease?
Current Alzheimer Research Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Early Features in Frontotemporal Dementia
Current Alzheimer Research Functional Autoradiography Shows Unaltered Cannabinoid CB1 Receptor Signalling in Hippocampus and Cortex of APP/PS1 Transgenic Mice
CNS & Neurological Disorders - Drug Targets Effect of Drugs in Cells and Tissues by NMR Spectroscopy
Current Topics in Medicinal Chemistry